FDA and VA Plan Joint AIDS Study

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 1
Volume 11
Issue 1

ROCKVILLE, Maryland-Researchers at the Food and Drug Administration and the Veteran’s Administrations will join in an effort to determine whether HIV infection or certain drugs used to treat it cause avascular necrosis (AVN). The disorder,

ROCKVILLE, Maryland—Researchers at the Food and Drug Administration and the Veteran’s Administrations will join in an effort to determine whether HIV infection or certain drugs used to treat it cause avascular necrosis (AVN). The disorder, the destruction of bone cells due to a deficient blood supply, commonly affects people with AIDS. The epidemiologic study will focus on suspected AVN cases registered with the Veterans Health Administration’s centralized HIV Registry, which contains data on approximately 50,000 patients.

Recent Videos
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content